is apparently confined to the lungs. The rationale of this approach is based upon the fact that although bulky disease responds dramatically to chemotherapy and tumour regression often occurs, large masses of teratoma are difficult to eradicate with radiotherapy but small volume residual disease may be more readily controlled. The influence of histology on response to chemotherapy which has been noted in all previous reports has been seen again in this series. It is really only the anaplastic teratomas which are consistently chemosensitive.
Since it is possible to eradicate large volumes of anaplastic tumours with chemotherapy, albeit transiently in most cases, this raises the possibility of using chemotherapy prophylactically following surgery and radiotherapy to increase the cure rate in patients whose disease is localized at the time of presentation. This approach has already been effective in cancers such as Wilms' tumour (D'Angio & Evans 1971) , Ewing's tumour (Johnson & Pomeroy 1972) , and rhabdomyosarcoma (Pratt et al. 1972 ), in which the major cause of treatment failure in patients with apparently localized tumours has been failure to control the growth of microscopical metastases which are already established at the time of presentation. At The Royal Marsden Hospital 50% of men with Stage IL (testis and para-aortic nodes only involved) anaplastic teratomas treated with surgery and radiotherapy have failed to survive three years (Smithers 1972b) despite their being apparently disease free after treatment is completed. It is in a group such as this that the addition of prophylactic chemotherapy may help to prolong survival by the eradication of undetected small metastases. Patients with more advanced disease will remain the proving ground for the testing of new primary drug treatments. 
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Radiotherapy of Testicular Tumours
Previous publications from the Testicular Tumour Unit of the Royal Marsden Hospital have reported the improvements which have occurred in the results of the radiotherapy of testicular tumours resulting from more precise clinical staging, the development of accurate radiation planning techniques and the introduction of super-voltage radiation equipment (Smithers 1972 , Smithers et al. 1971 . This report summarizes the results of treatment of patients with Stages 1, If and III seminoma and teratoma of the testis treated with radiotherapy between 1963 and 1971 and considers means whereby the prospects of patients with a high risk of disease relapse might be improved.
The clinical lymphographic staging is as follows: Stage I: tumour confined to testis (lymphogram negative). Stage HI: positive lymphogram (no supradiaphragmatic nodal disease). Stage III: supradiaphragmatic nodal disease (mediastinal and/or supraclavicular). Stage IV: extralymphatic spread (lungs, liver, brain &c.).
Histology
Histological material from patients in this series has been classified according to the histological classification adopted by the Testicular Tumour Panel of Great Britain (Collins & Pugh 1964) . The Macdonald, in preparation) and a detailed study of the radiation response in relation to retroperitoneal tumour mass is in progress. The lymphogram was positive in 26 % of seminoma patients. In teratoma patients with no other evidence of extralymphatic spread the positive lymphogram rate was as follows: MTA 12/35 (34%), MTI 9/34 (27%), MT trophoblastic 2/4 patients, combined tumours (teratoma and seminoma co-existing in the same testis) 13/29 (43 %).
Liver scanning, liver function tests, intravenous pyelography and, in teratoma patients, whole lung tomograms, are performed routinely. Nonstaging procedures include serum alphafetoprotein and urinary chorionic gonadotrophin assays. The usefulness of isotopic and ultrasonic scanning is being evaluated currently. Seminoma deposits have been found to incorporate gallium-67, but studies with gallium-67 and indium bleomycin in teratoma have proved disappointing. Liver needle biopsy, peritoneoscopy or diagnostic laparotomy have not been carried out except in exceptional circumstances, although in future these procedures may have to be considered in view of the critical importance of recognizing liver involvement, especially in malignant teratoma.
Treatment
The majority of patients were treated on the 6 MeV linear accelerator. Stage I patients receive irradiation to the para-aortic and ipsilateral pelvic nodes from T1O/1I1 interspace to the lower border of the obturator foramen. No attempt has been made to cover the orchidectomy scar, the inguinal nodes or scrotal sac if a routine high cord ligation was performed. If there is involvement of scrotal skin (a rarity), previous inguinal surgery (herniorrhaphy, orchidopexy), or if scrotal incision or testicular biopsy was performed, then the scrotal sac and inguinal nodes are included in the fields.
The contralateral testis is protected by 1 cm moulded lead shielding placed around the scrotal sac. When the lower border of the radiation field is located at the inferior region of the obturator foramen the dose received by the remaining testis is approximately 1.5 % of the nodal dose delivered by the linear accelerator. The effect of this dose on spermatogenesis has not been systematically examined; temporary oligospermia is likely but fertility is restored in a proportion of patients (Smithers etal. 1973) .
In Stage lI disease (positive lymphogram) the field is as described above unless there is bulky and/or low para-aortic disease. In this case, because of the risk of retrograde spread into contralateral pelvic nodes an inverted Y field is employed to irradiate the nodes on both sides of the pelvis. The width of the field is individualized but in general the field extends to the renal pelvis ensuring the protection of the bulk of the renal parenchyma.
In Stage IL and IIf patients the mediastinum and supraclavicular fossee are irradiated, an interval of approximately one month elapsing after the completion of abdominal irradiation. A tumour dose of 3000 rad in approximately 3f-4 weeks is given in seminoma and a minimum of 4000 rad in 4j-5 weeks in teratoma. Where there is obvious nodal involvement, a tumour dose of 4500 or 5000 rad is given. The tumoricidal dose in seminoma may well be less than 3000 rad in 3-4 weeks and in the 3 patients retreated for second primaries tumour control has apparently been secured with doses in the region of 1500-2000 rad. Bulky teratoma on the other hand is difficult to control with irradiation. In 8 patients where bulky nodes have only partially regressed an attempt was made to excise residual disease after irradiation. Elective retroperitoneal node dissection instead of, or as a preliminary to, irradiation has not been performed. In seminoma the exquisite radiosensitivity of the tumour facilitates irradiation of extralymphatic structures such as lung parenchyma and liver. In this group our limited experience with disseminated disease suggests that although alkylating agents achieve excellent disease regression, this is usually not maintained and for this reason every attempt should be made to irradiate all identifiable disease.
Results ofTreatment
The results of treatment are summarized (Table 1) for the following group of patients treated between 1963 and 1971 (follow up two to ten years): 110 seminoma patients (Stages I-IV), 34 MTI, 36 MTA, 4 trophoblastic tumours and 29 patients with combined tumours (Stages I-lII); 43 Stage IV teratomas were seen during this period and these are excluded from the analysis. 
Post-irradiation Lymph Node Dissection
In 8 teratoma patients in whom bulky retroperitoneal nodes regressed incompletely after irradiation, an attempt was made to resect residual tumour. In 2 patients widespread metastatic disease supervened within one year. In a third patient there was an apparent disease-free interval for four years when collapse of the body of L2 was followed by rapidly growing pulmonary metastases. Five patients are alive and disease free. In 2 there was histological confirmation of residual tumour, 1 patient received further irradiation combined with mithramycin and vinblastine, and the other actinomycin D.
Conclusions
Few patients with seminoma present with widespread disease. The prognosis in all stages for patients with this tumour is excellent. In both seminomas and teratomas lymphography is of great value for diagnosing the presence and demonstrating the extent of abdominal node involvement. The finding of abdominal node involvement modifies the therapeutic approach, mediastinal and cervical node irradiation being carried out and the contralateral pelvis irradiated if bulky or low para-aortic involvement is present. MTI+seminoma Dead not been tested in a controlled clinical study but retrospective comparison with previously treated patients and those treated with abdominal irradiation alone at other centres suggests that such an approach is of value (Smithers 1972 In Stage II anaplastic teratomas where the risk of disease relapse is high our policy is to follow irradiation with six courses of vinblastine, actinomycin D and methotrexate. It would be desirable to test the value ofadjunct chemotherapy in a clinical trial. This however would need to be a multicentre collaborative study in view of the rarity of this presentation.
The incidence of tumours of the contralateral testis in this series is 8/211 (4%). These tumours were detected on follow-up examination when they were small. Full investigations were repeated.
If the lymphogram was positive and the second tumour a seminoma the para-aortic node strip was re-treated to a dose of 1500 to 2000 rad. In those patients developing a teratoma as second tumour and where the lymphogram was negative no further treatment was instituted.
The low frequency in this series of second testicular primary tumours and the successful retrieval of 6 of the 8 patients who developed second tumours (providing an overall death rate of less than 1 % from second primaries), together with the preservation of fertility in many of these patients, fully vindicates a treatment policy of not irradiating the contralateral testis.
Radiotherapy ofStage IVPatients
In the case of limited Stage IV disease (for example, the finding of a pulmonary metastasis on whole lung tomography in a patient with otherwise localized disease) we have recently preferred to irradiate the retroperitoneal nodes followed by irradiation to both lung fields (2000 rad in 2j weeks), adding supplementary irradiation to pulmonary metastases and the mediastinal and cervical lymph node areas. Radiotherapy is followed after an interval of two months by six courses of triple chemotherapy. This policy is presently being evaluated both from the point of view of its effectiveness in controlling disease and the tolerance of normal tissue (particularly pulmonary parenchyma) to the combined regimen. Van der Werf-Messing (1973) employing 3000 rad mid plane dose in twenty fractions over four weeks with additional doses to visible metastases has reported a 50 % survival at thirty-two months in teratoma patients with small volume pulmonary metastatic disease. However, of 15 patients with localized pulmonary metastases, 5 developed serious pneumonitis and we have preferred to employ a low dose especially since pulmonary radiation damage is almost certainly exacerbated by post-irradiation intensive chemotherapy.
In more advanced Stage IV disease an attempt is being made to induce a complete remission with chemotherapy and follow this by a systematic irradiation of the initial disease sites (McElwain & Peckham 1974) .
